Application of lactobacillus acidophilus in regulating intestinal flora and treating cholestatic liver disease

By activating the small intestine FXR signal and enhancing BSH enzyme activity, regulating the intestinal flora-FXR-bile acid axis, the treatment problem of intrahepatic cholestasis liver disease is solved, and cholestasis liver damage is significantly reduced and improved Liver function indicators provide new treatment options for clinical practice.

CN118976050APending Publication Date: 2024-11-19THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410552753.7
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-05-07
Publication Date
2024-11-19

AI Technical Summary

Technical Problem

The prior art is difficult to effectively treat cholestatic liver disease, especially intrahepatic cholestatic liver disease, and the imbalance of intestinal flora is involved in the disease progression, but the effects of existing probiotics on different body states are inconsistent.

Method used

Lactobacillus acidophilus is used to inhibit hepatic bile acid synthesis by activating the FXR signal in the small intestine, and promote bile acid excretion through BSH enzymes, and regulate the intestinal flora-FXR-bile acid axis to prepare drugs for the treatment of cholestatic liver disease.

Benefits of technology

Lactobacillus acidophilus significantly reduces cholestatic liver damage, and improves liver function indicators of cholestatic liver disease by increasing fecal bile acid excretion and improving liver function indicators of cholestatic liver disease.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118976050A_ABST
    Figure CN118976050A_ABST
Patent Text Reader

Abstract

The invention discloses application of lactobacillus acidophilus in preparation of medicines for regulating intestinal flora and improving cholestatic liver diseases. The lactobacillus acidophilus has the beneficial effects that the action mechanism that the lactobacillus acidophilus reduces liver CYP7A1 by activating intestinal FXR-FGF15, promotes non-binding bile acid conversion and increases excrement bile acid excretion so as to improve the cholestatic liver disease is found and confirmed, and a novel intervention mode is provided for clinical treatment of the cholestatic liver disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of biomedicine, and specifically relates to the use of Lactobacillus acidophilus in regulating intestinal flora and treating cholestatic liver disease. Background Art

[0002] Cholestasis refers to a pathological state in which bile cannot flow normally into the duodenum and enters the blood. It is a disorder of bile formation, secretion and excretion caused by different reasons. Clinical manifestations include itching, fatigue, dark urine and jaundice. In the early stage, there are often no symptoms. In severe cases, it can lead to liver failure or even death. Hepatobiliary diseases with liver lesions and cholestasis as the main manifestation due to various reasons are collectively referred to as cholestatic liver diseases. Cholestasis can be divided into intrahepatic and extrahepatic cholestasis according to the anatomical location of the stasis. The former occurs in the liver and the latter occurs in the biliary system. Adult cholestasis can be divided into many types according to the cause, including obstructive cholestasis such as gallstones, malignant tumors, common bile duct stenosis, bile duct lesions such as primary biliary cirrhosis, non-obstructive cholestasis such as infection, poisoning, hereditary diseases, pregnancy, etc.

[0003] In recent years, the concept of the gut-liver axis has been proposed and extensive research on intestinal microecology has shown that an imbalance in the intestinal flora can be involved in the progression of most diseases. According to statistics, the number of flora colonizing the human intestine is about 10 times the number of cells, with more than 1,000 species, which significantly exceeds the number of human genomes. Therefore, the intestinal flora is considered to be one of the important regulatory "organs" of the human body. Numerous studies have shown that the intestinal flora can functionally affect human health in many ways, such as helping the human body digest, absorb and metabolize food. Probiotics in the intestinal flora can prevent the overgrowth of pathogens, resist the invasion of exogenous pathogens or infection by conditional pathogens, and can also participate in the host's metabolism and immune function regulation. More importantly, as the main site for drug absorption, the intestinal flora can affect the metabolism and efficacy of drugs. The strains considered as probiotics in the prior art are not always beneficial to patients with different body states. For example, patent document CN114010665A discloses that Lactobacillus reuteri has a mitigating effect on alcoholic liver disease; Martoni et al. (Martoni, et al. Changes in bile acids, FGF-19 and sterol absorption in response to bile salthydrolase active L. reuteri NCIMB 30242. Gut Microbe, 2015, 6: 57-65.) found that Lactobacillus reuteri not only reduces the concentration of low-density cholesterol (LDL-C) in the blood, but also stimulates the FXR axis and increases the level of circulating bile acids, which is beneficial to lowering blood lipids; and there is a document (Pandey SP, et al. Tet2 deficiency drives liver microbiome dysbiosis triggering Tc1 cell autoimmune hepatitis. Cell HostMicrobe.2022) reported that Lactobacillus reuteri can induce autoimmune hepatitis in Tet2-deficient mice, and autoimmune hepatitis can also lead to intrahepatic cholestasis. There are multiple literature reports that intestinal flora can participate in bile acid metabolism, for example: Patent document CN117264810A discloses the use of probiotic compositions to prepare preparations that can limit bile acid synthesis function, and patent document CN117883485A reports that Bifidobacterium longum CCFM1077 has the effect of alleviating intrahepatic cholestasis.

[0004] Lactobacillus acidophilus is one of the edible fungi approved by the Ministry of Health for infants and young children, and it has the closest relationship with the human body. In recent years, the clinical therapeutic use of Lactobacillus acidophilus has received widespread attention. A large number of studies have shown that the bacteria can reduce the load of Helicobacter pylori, downregulate host proinflammatory cytokines and tight junction proteins to maintain cell morphology and integrity and improve lactose intolerance. At present, the American Clinical Research Center has entered the clinical trial stage for the treatment of Lactobacillus acidophilus for cirrhosis infection (registration number: NCT01607528), Clostridium difficile infection in the elderly (registration number: NCT01680874), and combined quadruple therapy to eliminate Helicobacter pylori infection (registration number: NCT03377933). Clinical research results have shown that the bacteria can effectively reduce the symptoms of upper respiratory tract infections in children and relieve oral mucositis caused by radiotherapy and chemotherapy, suggesting that the bacteria has potential therapeutic effects on a variety of diseases.

[0005] The inventors of the present application have found that Lactobacillus acidophilus has a potential therapeutic effect on cholestatic liver disease, and through animal experiments, bioinformatics analysis and clinical studies, it has been confirmed that Lactobacillus acidophilus has the effect of alleviating cholestatic liver damage. The specific mechanism is to inhibit hepatic bile acid synthesis by activating the small intestinal FXR signal, and promote bile acid excretion through BSH enzyme, ultimately improving liver damage in mice with cholestatic liver disease. This study discovered and confirmed the mechanism of action of Lactobacillus acidophilus in improving cholestatic liver disease by regulating the intestinal flora-FXR-bile acid axis, providing a new treatment method for clinical treatment, and the present invention is proposed accordingly. Summary of the invention

[0006] In view of this, one of the objects of the present invention is to provide a use of Lactobacillus acidophilus in regulating the intestinal flora of humans or other mammals.

[0007] The technical solution is as follows:

[0008] Application of Lactobacillus acidophilus in the preparation of medicines for regulating intestinal flora of humans or other mammals.

[0009] Lactobacillus acidophilus is used as the only active bacteria in the medicament or together with active bacteria of other species.

[0010] The second object of the present invention is to provide the use of Lactobacillus acidophilus in the preparation of a medicine for intrahepatic cholestatic liver disease.

[0011] Application of Lactobacillus acidophilus in preparing medicine for treating intrahepatic cholestatic liver disease in human or other mammals.

[0012] In one embodiment, the above-mentioned drug can regulate intestinal flora, reduce bile acid synthesis and promote bile acid excretion.

[0013] In one embodiment, the above-mentioned drug can increase the abundance of Lactobacillus acidophilus in the intestinal flora of humans or other mammals, and inhibit hepatic bile acid synthesis by activating intestinal farnesoid X receptor signaling.

[0014] In one embodiment, the above-mentioned drug increases the abundance of lactobacillus bacteria in the intestines of humans or other mammals and increases the ratio of unconjugated bile acid by enhancing the activity of bile salt hydrolase, thereby promoting fecal bile acid excretion.

[0015] In one embodiment, the above-mentioned cholestatic liver disease is of obstructive cholestasis type.

[0016] In one embodiment, the above-mentioned medicine contains Lactobacillus acidophilus, with or without pharmaceutical adjuvants.

[0017] In one embodiment, the pharmaceutical excipient is a pharmaceutically acceptable carrier or excipient. For example, the pharmaceutical excipient can be a coating carrier of active bacteria, or other drug ingredients to form a compound component.

[0018] The medicine contains only one active bacterium, Lactobacillus acidophilus, or the medicine also contains active bacteria of other genera. The active bacteria of other genera may be probiotics commonly used in clinical practice.

[0019] In one embodiment, the strain number of Lactobacillus acidophilus is ATCC4356.

[0020] The third object of the present invention is to provide the use of the compound Lactobacillus acidophilus tablets in the preparation of drugs for intrahepatic cholestatic liver disease.

[0021] The invention discloses an application of a compound lactobacillus acidophilus tablet in preparing a medicine for treating intrahepatic cholestatic liver disease in humans or other mammals. The compound lactobacillus acidophilus tablet comprises four bacterial powders, namely, Chinese strain of lactobacillus acidophilus, Japanese strain of lactobacillus acidophilus, streptococcus faecalis and bacillus subtilis.

[0022] The invention discloses a method for preparing a medicine for treating intrahepatic cholestatic liver disease in humans or other mammals by combining compound lactobacillus acidophilus tablets with ursodeoxycholic acid. BRIEF DESCRIPTION OF THE DRAWINGS

[0023] Figure 1 Comparison of symptom-related indicators of cholestatic liver disease mice with different symptom severity, including: (A) serum ALT, AST, TBA and ALP, (B) liver HE staining and quantification of hepatocyte necrosis expression, (C) F4 / 80 immunofluorescence staining and quantification of positive areas, (D) mRNA expression of liver inflammation-related molecules; Severe represents the severe group, and Mild represents the mild group; *p<0.05, **p<0.01; scale bars in (B) and (C) are 100μm and 200μm, respectively.

[0024] Figure 2 The results of fecal microbiota transplantation in cholestatic mice include: (A) flow chart of fecal microbiota transplantation in mice, (B) serum ALT, AST, TBA and ALP, (C) liver HE staining and quantification of hepatocyte necrosis, (D) F4 / 80 immunofluorescence staining and quantification of positive areas, (E) mRNA expression of liver inflammation-related molecules; FMT(Severe)→WT represents the WT mouse group that received severe mouse fecal microbiota transplantation, and FMT(Mild)→WT represents the WT mouse group that received mild mouse fecal microbiota transplantation; *p<0.05, **p<0.01; scale bars in (B) and (C) are 100μm and 200μm, respectively.

[0025] Figure 3 (3-1, 3-2) shows the differences in intestinal flora of mice with cholestasis symptoms of different severity, including: (A) heat map of different bacterial genera between mild and severe groups of mice, (B) phylum level bar chart, (C) genus level bar chart, (D)-(E) Chao1 and Simpson_e diversity expression, (F)-(G) Bray-Curtis and Jaccard diversity expression, (H)-(I) LEfSe analysis, (J) volcano plot showing the relative abundance distribution of microbial OTUs, (K) fecal mRNA level of Lactobacillus acidophilus; Severe represents the severe group and Mild represents the mild group.

[0026] Figure 4 The results of the experiment to study the therapeutic effect of Lactobacillus acidophilus on BDL mice showed that it had the effect of alleviating liver damage, including: (A) Flow chart of the bacterial treatment mouse experiment, (B) Serum ALT, AST and TBA, (C) Liver HE staining and quantification of hepatocyte necrosis expression, (D) F4 / 80 immunofluorescence staining and quantification of positive areas, (E) mRNA expression of liver inflammation-related molecules; Sham is the sham operation group, BDL is the common bile duct ligation model group, and BDL+L.acidophilus is the Lactobacillus acidophilus gavage group after common bile duct obstruction; *p<0.05, **p<0.01; The scale bars in Figures (C) and (D) are 100μm and 200μm, respectively.

[0027] Figure 5The results of the analysis of the bile acid profile of BDL mice after treatment with Lactobacillus acidophilus indicate that supplementation with Lactobacillus acidophilus can reduce the total amount of hepatic bile acid and increase fecal bile acid excretion, including: (A)-(B) classification and profile of liver bile acids in mice with severe and mild injuries, (C)-(D) classification and profile of fecal bile acids in mice with severe and mild injuries, (E)-(F) classification and profile of liver bile acids after treatment with Lactobacillus acidophilus, (G)-(H) classification and profile of fecal bile acids after treatment with Lactobacillus acidophilus; Severe represents the severe group, Mild represents the mild group, Sham represents the sham operation group, BDL represents the common bile duct ligation modeling group, and BDL+L.acidophilus represents the Lactobacillus acidophilus gavage group after common bile duct ligation; *P<0.05, **P<0.01, ***P<0.001, P<0.0001.

[0028] Figure 6 Figure 3 Effects of Lactobacillus acidophilus on bile acid metabolism in mice with hepatic cholestasis, indicating that it reduces hepatic bile acid synthesis through FXR receptor to improve cholestatic liver injury, including: (A) conjugated / unconjugated bile acid ratio in feces of severe and mild mice, (B) conjugated / unconjugated bile acid ratio in feces of mice after sham, BDL and BDL+Lactobacillus acidophilus treatment, (C) fecal BSH enzyme activity of severe and mild mice, (D)-(E) ileal FGF15 and FXR mRNA expression; (F) liver CYP7α1 mRNA expression, (G)-(I) serum ALT, AST, TBA levels, (J) liver HE staining and quantification of hepatocyte necrosis expression, (K) F4 / 80 immunofluorescence staining and quantification of positive area; Severe represents the severe group, Mild represents the mild group, Sham represents the sham operation group, BDL represents the common bile duct ligation modeling group, and BDL+L.acidophilus represents the Lactobacillus acidophilus gavage group after common bile duct ligation; *p<0.05, **p<0.01, ***p<0.001; the scale bars in Figures (J) and (K) are 100μm and 200μm, respectively.

[0029] Figure 7 These are the experimental results of the intervention effect of Lactobacillus acidophilus on patients with cholestatic liver disease, including: (A)-(E) serum ALT, AST, ALP, GGT and TBIL and the correlation between the abundance of lactobacillus and serum ALT, AST, ALP, GGT and TBIL using Spearman correlation analysis; UDCA represents the ursodeoxycholic acid treatment group, and UDCA+L.acid represents the ursodeoxycholic acid combined with Lactobacillus acidophilus treatment group.

[0030] Figure 8Effects of Lactobacillus acidophilus treatment on the intestinal flora structure of patients with cholestatic liver disease, including: (A) Chao1 and Heip_e diversity in fecal 16S sequencing of the two groups of subjects on day 0, (B) Bray-Curtis and Jaccard diversity in fecal 16S sequencing of the two groups of subjects on day 0, (C) Chao1 and Heip_e diversity in fecal 16S sequencing of the two groups of subjects on day 14, (D) Bray-Curtis and Jaccard diversity in fecal 16S sequencing of the two groups of subjects on day 14; UDCA represents the ursodeoxycholic acid treatment group, and UDCA+L.acid represents the ursodeoxycholic acid combined with Lactobacillus acidophilus treatment group.

[0031] Fig. 9 Effects of Lactobacillus acidophilus on bile acid profile in patients with cholestatic liver disease, including: (A) serum bile acid levels after UDCA treatment alone or in combination with Lactobacillus acidophilus, (B) fecal bile acid levels after UDCA treatment alone or in combination with Lactobacillus acidophilus, (C) fecal conjugated / unconjugated bile acid ratio after UDCA treatment alone or in combination with Lactobacillus acidophilus, (D) fecal bile acid profile before treatment and after UDCA combined with Lactobacillus acidophilus treatment; UDCA represents the ursodeoxycholic acid treatment group, UDCA+L.acid represents the ursodeoxycholic acid combined with Lactobacillus acidophilus treatment group, CLI represents the cholestatic liver injury group before treatment, and CLI+L.acid represents the cholestatic liver injury group after UDCA combined with Lactobacillus acidophilus treatment.

[0032] The meanings of some English abbreviations in the text are as follows: ABX, antibiotics; ALT, alanine aminotransferase; AST, aspartate aminotransferase; BSH, bile salt hydrolase; CDCA, chenodeoxycholic acid; FXR, farnesoid X receptor; BDL, bile duct ligation; FMT, fecal microbiota transplantation; BAs, bile acids; Lactobacillus acidophilus; SCFAs, short-chain fatty acids; PBC, primary biliary cholangitis; PSC, primary sclerosing cholangitis; PBS, phosphate-buffered saline; OTUs, operational taxonomy units; qRT-PCR, real-time quantitative PCR; ANOSIM, similarity analysis; PCo A, commands to calculate principal coordinates analysis; LDA, linear discriminant analysis; LEfSe, linear discriminant analysis effect size; TNF-α, tumor necrosis factor-α; IL-6, interleukin-6; IL-1β, interleukin-1β; WT, wild type; FXR, farnesoid X receptor; SHP, small heterodimeric ligand; FGF15, fibroblast growth factor; CYP7α1, cholesterol 7α hydroxylase; TBA, total bile acid; ALP, alkaline phosphatase; TBIL, total bilirubin; CA, cholic acid; DCA, deoxycholic acid; UDCA, ursodeoxycholic acid; GU, FXR inhibitor; BSH, bile salt hydrolase. DETAILED DESCRIPTION

[0033] The present invention is further described below in conjunction with embodiments and drawings.

[0034] Embodiment 1

[0035] 1.1 Gut flora mediates the progression of cholestatic liver disease

[0036] Experimental Materials and Methods

[0037] 1.1.1 Establishment of mouse common bile duct ligation model

[0038] WT male mice of 8 weeks old, weighing 22-25g, were selected for the experiment after one week of adaptive feeding. The mice were fasted for 8 hours before the operation and anesthetized by inhalation gas. After entering the anesthesia state, they were fixed in the supine position on the operating table, routinely disinfected and draped, and the hair was shaved to fully expose the abdomen. Anesthesia was maintained during the operation. After repeated disinfection, the common bile duct was explored and freed, and the 6-0 silk thread was double ligated. After confirming that there was no bleeding or damage to the abdominal organs, the abdomen was closed layer by layer. After the operation, the mice were placed in a clean and warm environment for resuscitation to establish the BDL mouse model. The whole process was kept in a clean standard. After the operation, the mice were fed observationally, the weight and yellowing of the skin and mucous membranes of the mice were recorded every day, and the median survival of the mice after the operation was calculated.

[0039] 1.1.2 Evaluation of the severity of cholestatic liver injury

[0040] (1) Mice were killed and the corresponding samples were collected. Blood was quickly collected and liver tissue was separated to obtain liver weight (= liver wet weight g / mouse body weight g*1000%). After standing at room temperature for 4 hours, centrifuged at 3000 rpm for 10 minutes at room temperature, the upper serum was aspirated, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bile acid (TBA) were detected, and liver H&E staining and F4 / 80 immunofluorescence staining and scoring were performed.

[0041] (2) qRT-PCR detection (SYBR Green method) of mRNA expression of liver inflammation-related molecules.

[0042] Experimental Results

[0043] The BDL mouse model established by bile duct ligation is a bile duct obstructive cholestatic liver disease model, which is a commonly used model in related research and has definite typical cholestatic symptoms. The experimental results showed that through postoperative observation of BDL mice, they can be divided into two groups according to the median survival time, namely severe and mild. Compared with mild mice, Figure 1 As shown in A, ALT, AST, TBA, and ALP in heavy mice increased significantly; Figure 1 As shown in B-1C, special staining of the liver, including H&E staining and F4 / 80 immunofluorescence staining, indicates that BDL model mice have typical liver injury manifestations, and the liver injury in severe mice is more severe. Figure 1 As shown in D, the expression levels of a series of inflammation-related markers, TNF-α, IL-1β, IL-6, and F4 / 80, in the liver tissue of severe mice were significantly higher than those of mild mice. The above results suggest that liver damage in cholestatic mice can be mild or severe.

[0044] 1.1.3 Fecal microbiota transplantation (FMT) experiment

[0045] (1) Preparation of fecal microbiota transplantation suspension: fresh feces of mild and severe mice were taken, resuspended in sterile PBS, centrifuged at 1000 rpm for 1 minute at room temperature to precipitate impurities, and the supernatant was retained as fecal microbiota suspension for later use;

[0046] (2) Transplantation mouse preparation: Transplant recipient mice were obtained by gavage of WT mice with the ABX regimen (ampicillin 200 mg / kg, neomycin 200 mg / kg, metronidazole 200 mg / kg, and vancomycin 100 mg / kg) for 5 days;

[0047] (3) FMT: Orally gavaged WT mice were randomly divided into two groups. The WT mice that were to receive severe mouse fecal microbiota transplantation were designated as the FMT(Severe)→WT group, and the WT mice that were to receive mild mouse fecal microbiota transplantation were designated as the FMT(Mild)→WT group. The prepared fecal microbiota suspension was transplanted into FMT(Severe)→WT and FMT(Mild)→WT mice by oral gavage (200 μl / mouse / day for a total of 5 days). After modeling, the body weight and liver weight of the mice were recorded.

[0048] (4) The degree of liver injury was evaluated according to the above method. Serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), alkaline phosphatase (ALP) and total bile acid (TBA) were detected, and liver H&E staining and F4 / 80 immunofluorescence staining and scoring were performed. qRT-PCR detection (SYBR Green method) was used to detect the mRNA expression of liver inflammation-related molecules. The experimental process was as follows Figure 2 A gesture.

[0049] Experimental Results

[0050] The results showed that Figure 2As shown in B-2E, compared with the FMT(Severe)→WT group, the serum AST, ALT, and TBA in the FMT(Mild)→WT group were significantly reduced, and there was less hepatocyte necrosis. The liver TNF-α, IL-1β, IL-6, and F4 / 80 levels were higher in the FMT(Severe)→WT transplantation group. These data suggest that the intestinal microbiota is involved in cholestatic liver injury.

[0051] 1.1.4 16S rRNA high-throughput sequencing and analysis

[0052] (1) Sample collection

[0053] Fecal samples of BDL model mice and FMT mice in the experiment of Example 1 were collected by massaging the mouse rectum and stored in sterile 1.5 mL centrifuge tubes (at least 3 pellets per tube) at -80°C. They were transported to Novogene (Tianjin, China) via dry ice cold chain for fecal genomic DNA extraction, library establishment, and sequencing on the Illumina high-throughput sequencing platform NovaSeq6000. The sequencing process is described briefly as follows with reference to the website https: / / novogene.com:

[0054] A: Genomic DNA extraction and PCR amplification

[0055] Extract the genomic DNA of the sample, detect the purity and concentration of the DNA by agarose gel electrophoresis, take an appropriate amount of sample DNA into a centrifuge tube, and dilute the sample with sterile water to a concentration of 1 ng / μL.

[0056] To ensure amplification efficiency and accuracy, diluted genomic DNA was used as a template and specific primers with barcodes were used according to the selection of sequencing regions. High-Fidelity PCR Master Mix with GC Buffer, and high-efficiency and high-fidelity enzymes for PCR.

[0057] B: Mixing and purification of PCR products

[0058] The PCR product was detected by electrophoresis using 2% agarose gel; equal amounts of samples were mixed according to the concentration of the PCR product, and after sufficient mixing, the PCR product was detected by 2% agarose gel electrophoresis, and the target band was recovered using a gel recovery kit provided by QIAGEN.

[0059] C: Library construction and sequencing

[0060] use The library was constructed using the DNA PCR-Free Sample Preparation Kit. The constructed library was quantified by Qubit and Q-PCR. After the library was qualified, it was sequenced using NovaSeq6000.

[0061] D: Wait for the Raw data to be returned before proceeding to the next step of analysis.

[0062] (2) Analysis process

[0063] Microbial community annotation: The QIIME2 (version number: 2020.2) platform was used in the conda environment to process the sequencing data. In short, the V3-V4 primers of the double-end fastq format sequence files were cut using the cutadapt 3.1 command in Python 3.6.9. Then, the cut fastq files were imported into QIIME2 using the “qiime tools import” command. Next, by using the “qiime dada2 denoise-paired” command, the reads were denoised into amplicon sequence variants (ASVs), and a representative sequence and feature table for each ASV was generated. In addition, since DADA2 already includes internal chimera checking methods and abundance filtering, additional filtering is no longer required. After the DADA2 denoising step is completed, the “qiimefeature-table summarize” command is used to generate a feature table summary report, which lists the number of sequences associated with each sample and each feature. During this process, samples with a sampling depth of less than 8000 (Non-chimeric sequences) were excluded from further analysis. All samples were then rarefied to the same depth by the “qiime feature-table rarefy” command, and a sparse feature table was generated. Next, Beta diversity was calculated from the sparse feature table by the “qiime diversity beta” command. After calculating the diversity, the principal coordinate analysis (PCoA) analysis results were calculated by the “qiime diversity pcoa” command and visualized by the “qiime emperor plot” command. Next, an Analysis of Similarities (ANOSIM) analysis was performed to calculate the significant differences in similarities (Dissimilarity values). Then, the pre-trained naive Bayes classifier (silva-132-99-nb-classifier.qza, trained on SILVA 132 99% full-length sequences) and the “qiime feature-classifier classify-sklearn” command were used to explore the taxonomic composition of the samples.Next, the linear discriminant analysis effect size (LEfSe) (http: / / huttenhower.sph.harvard.edu / lefse) (the linear discriminant analysis (LDA) score (log10) = 2 was selected as the cutoff value) was used to further analyze the dominant bacteria in the bacterial communities between the groups.

[0064] 1.1.5 Data processing and statistical analysis

[0065] Experimental Results

[0066] The results showed that, as shown in the figure, the heat map showed 13 bacterial genera with significant statistical differences at the genus level between the light and heavy groups of mice (Figure 3A). The results showed that at the genus level, the intestinal flora of the heavy group of mice was rich in Alloprevotella, Enterococcus, Escherichia_Shigella, Helicobacter and Lachnospiraceae_NK4A136_group, while the intestinal flora of the light group of mice was rich in Enterobacter, Lactobacillus and Ruminococcaceae_UCG_014 (Figure 3B-C). There was no difference in α diversity between the two groups of mice (P>0.05) (Figure 3D-E). β diversity indicated that there were significant differences in the composition of the intestinal flora (P≤0.01) (Figure 3F-G). In addition, in order to further find bacterial markers with statistical significance and biological relevance, LEfSe was used for high-dimensional data analysis (LDA score ≥2 was selected as the cutoff value), and the results showed that Lactobacillus was marked between the two groups (Figure 3H). The volcano plot also identified Lactobacillus as a key genus (Figure 3J). qRT-PCR detection (SYBR Green method) confirmed that the abundance of Lactobacillus acidophilus was significantly different between the two groups of mice (Figure 3K).

[0067] Embodiment 2

[0068] 2.1 Lactobacillus acidophilus can alleviate cholestatic liver damage

[0069] Experimental Materials and Methods

[0070] 2.1.1Lactobacillus acidophilus (L.acidophilus) strain

[0071] (1) Bacterial recovery, culture, subculture and cryopreservation

[0072] The recovery, culture, subculture and cryopreservation of bacteria are all completed in a clean bench after sterilization with ultraviolet light.

[0073] 1) Recovery and culture: L.acidophilus strains were purchased from the American Type Culture Collection (ATCC4356). The vials were opened according to the instructions attached. The brief process is as follows: Take out the strains from the -80℃ refrigerator, light an alcohol lamp in the clean bench, and hydrate the entire strain freeze-dried powder with about 0.5mL of MRS culture medium next to the flame of the alcohol lamp. Then use a sterile pipette to absorb all the bacterial liquid, drop it on the blood plate in mid-air, and evenly apply it with a sterile inoculation loop. After the liquid is completely in the plate, cover it with a lid, invert it in an anaerobic culture bag, and culture it in a 37℃ carbon dioxide incubator for 24 to 48 hours.

[0074] 2) Subculturing: Aseptically transfer all the contents on the plate to 5-6 mL of MRS medium, and continue to expand the culture in an anaerobic culture bag at 37°C for 24-48 hours. Note that the bacteria should not be shaken. Subculturing is performed by transferring 0.5 mL of primary liquid culture medium to secondary liquid culture medium (0.5 mL: 5-6 mL). Note that the test tube screw cap should be loosened slightly and cultured in an anaerobic culture bag at 37°C for 24-48 hours.

[0075] 3) Cryopreservation: Take an appropriate amount of bacterial solution and put it into a 1.5 mL sterile cryopreservation tube, add sterile glycerol (final concentration is 20-30%), mix well and seal with sealing film, write the strain name, generation and time, and store at -80℃.

[0076] (2) L. acidophilus single bacteria gavage experiment

[0077] In order to confirm the effect of L.acidophilus in BDL mice, the mice were randomly divided into the following three groups: ① sham group (Sham) + PBS; ② BDL + PBS; ③ BDL + L.acidophilus (MRS medium). The above groups were gavaged twice a day, with a gavage volume of 200 μl / mouse each time, and the bacterial cell volume in the bacterial solution was about 1×10 8 CFU for 9 days. On the last day, mice were fasted for 12 hours and then sacrificed. Whole blood, liver, colon, cecum and its contents, stool samples, etc. were collected and frozen in liquid nitrogen or -80℃ for later use. Figure 4 A.

[0078] 2.1.2 Evaluation of liver damage in each group of mice

[0079] (1) Mice were killed and relevant samples were collected. Blood was quickly collected and liver tissue was separated to obtain liver weight (= liver wet weight g / mouse body weight g*1000%). After standing at room temperature for 4 hours, the mixture was centrifuged at 3000 rpm for 10 min at room temperature, and the upper serum was aspirated to detect serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bile acid (TBA). Liver H&E staining and F4 / 80 immunofluorescence staining and scoring were performed.

[0080] (2) qRT-PCR detection (SYBR Green method) of mRNA expression of liver inflammation-related molecules.

[0081] Experimental Results

[0082] The results showed that compared with BDL mice, Figure 4 As shown in B, ALT, AST, and TBA in BDL+L.acidophilus (MRS medium) mice were significantly reduced; Figure 4 As shown in C to 4D, special staining of the liver, including H&E staining and F4 / 80 immunofluorescence staining, showed that BDL mice had typical liver damage, and the mice were significantly relieved after receiving L.acidophilus treatment. Figure 4 As shown in E, the expression levels of a series of inflammation-related markers, TNF-α, IL-1β, IL-6 and F4 / 80, in the liver tissue of BDL mice were significantly higher than those in BDL+L.acidophilus (MRS medium) mice. The above results suggest that Lactobacillus acidophilus has the effect of alleviating cholestatic liver injury.

[0083] Embodiment 3

[0084] 3.1 Detection of bile acid profiles in mild and severe mice and before and after Lactobacillus acidophilus treatment

[0085] Experimental Materials and Methods

[0086] (1) Quantitative analysis of bile acids

[0087] Liver and fecal samples of the light and heavy groups of mice in Example 1, and the Sham, BDL+PBS, and BDL+L.acidophilus treated mice in Example 2 were collected and transported on dry ice to Panomik Biopharmaceutical Technology Co., Ltd. (Suzhou, China) for bile acid targeted metabolomics detection. The detection process is briefly described as follows:

[0088] 1) Sample pretreatment

[0089] Add the ground liver sample (50 μL / sample) to a 96-well plate, and then add 400 μL of a mixed solvent of acetonitrile / methanol (volume ratio of 8:2) containing an internal standard. Centrifuge at 10°C and 650 rpm for 20 min. Then take 250 μL of the supernatant and transfer it to a 350 μL microplate, and further freeze-dry it in a freeze dryer equipped with a stop tray system. The dried actual sample, standard curve, and quality control sample powders are first added with 40 μL of acetonitrile / methanol (volume ratio of 8:2) solution, centrifuged at 10°C and 650 rpm for 20 min, and then 60 μL of deionized water is added, and centrifuged at 10°C and 650 rpm for 20 min. After shaking, freeze the microplate at -20°C for 20 min; then centrifuge at 4°C and 4000 g for 30 min before testing. The injection volume is 5 μL.

[0090] 2) Instrument parameters

[0091] Ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS / MS, ACQUITY UPLC-Xevo TQ-S, Waters Corp., Milford, USA) was used to quantify bile acids.

[0092] 3) Analysis methods

[0093] Quantification was performed by Panomik Biopharmaceuticals Technology Co., Ltd. (Suzhou, China). Briefly, the raw data files generated by UPLC-MS / MS were processed in MassLynx software (v4.1, Waters, Milford, USA), which integrated each bile acid, established a standard curve, and performed the quantification process. Mass spectrometry-based quantitative metabolomics obtains the actual concentration by comparing the metabolites in the unknown concentration sample with a set of standard samples of known concentration (quantification curve). The quantitative curve is a curve of the analytical signal as the concentration of the analyte (test substance) changes. Generally speaking, the relationship between the instrument response and the concentration will show a linear relationship. The regression equation will be generated as follows: y = ax + b, where y is the corresponding peak height or peak area of ​​the instrument, a is the slope / sensitivity, and b is a constant representing the background signal). The concentration of the analyte in the unknown sample (x) is calculated based on this equation.

[0094] Experimental Results

[0095] The results showed that Figure 5 As shown, the liver bile acid level of mild mice was lower than that of heavy mice (P < 0.05) ( Figure 5 A), mainly manifested by the decrease of CA and CDCA (P<0.05) ( Figure 5 B), fecal BAs excretion was higher (P<0.05) ( Figure 5 C), mainly manifested by the increase of CA (P<0.05) and DCA (P<0.05) ( Figure 5 D). Similarly, BDL mice treated with Lactobacillus acidophilus showed the same results ( Figure 5 EH).

[0096] 3.2 Lactobacillus acidophilus improves cholestatic liver injury in mice by activating ileal FXR signaling

[0097] Experimental Materials and Methods

[0098] (1) Detection of fecal BSH enzyme activity

[0099] After fecal protein extraction, it was placed in a 96-well plate and incubated for 8 hours at pH 5.8 and 37°C. In a total volume of 200 μl, 500 μg of fecal protein was incubated with sodium phosphate buffer (pH 5.8, final concentration of 0.02 mM) and taurodeoxycholic acid (TDCA). To prevent evaporation during incubation, 50 μl of paraffin oil (0.85 g / ml) was added to each well, and the samples were measured in triplicate and measured at 570 nm using a microplate reader. Phosphate-buffered saline was used as a negative control for fecal protein incubation, and a standard curve was established for fecal protein incubated with different concentrations of deoxycholic acid for quantification.

[0100] (2) Clarifying the role of FXR signaling

[0101] 1) qRT-PCR detection (SYBR Green method) of the mRNA expression of FXR downstream signaling-related molecules in the ileum.

[0102] 2) Preparation of FXR antagonist ((Z)-guggulsterone, GU)

[0103] The purchased FXR antagonist ((Z)-guggulsterone, GU) was taken out from -20℃, DMSO (5mg / mL) was added to dissolve it, mixed well, and then divided into individual portions, sealed with sealing film, and the name and time were written. The dosage was 200μl / piece, and it was stored at -20℃ for 9 consecutive days.

[0104] 3) Establishment of mouse BDL model and treatment and antagonism

[0105] According to the method in Example 1, mice were randomly divided into four groups: Sham, BDL, BDL+L.acidophilus, and BDL+L.acidophilus+GU. According to the method in Example 2, mice were intragastrically administered with single bacteria and antagonists.

[0106] 4) According to the method in Example 1, mice were killed and corresponding samples were collected to detect serum ALT, AST and TBA levels, and liver H&E staining and F4 / 80 immunofluorescence staining and scoring were performed.

[0107] Experimental Results

[0108] It was found that, based on the above experimental results, in the light and heavy groups of mice and in the BDL mice treated with Lactobacillus acidophilus, the ratio of conjugated bile acids to unconjugated bile acids in the feces of BDL mice with mild liver injury changed, and the change in the conjugated / unconjugated bile acid ratio was determined by the fecal BSH enzyme activity. The results suggested that there were more unconjugated bile acids in the feces of light mice and BDL mice treated with Lactobacillus acidophilus, so more fecal bile acids were excreted ( Figure 6 A-C). Activating the ileal FXR-SHP-FGF15 signal can inhibit the expression of hepatic CYP7A1, so the hepatic synthesis of bile acids is reduced ( Figure 6 D-F). To further verify the role of the FXR signal, BDL mice treated with Lactobacillus acidophilus were treated with GU simultaneously, and the results showed that the therapeutic effect of Lactobacillus acidophilus was eliminated ( Figure 6 G-K).

[0109] Example 4

[0110] 4.1 Effects of Lactobacillus acidophilus on patients with cholestatic liver disease

[0111] Experimental Materials and Methods

[0112] (1) Clinical research protocol

[0113] 1) Ethical review and informed consent

[0114] This clinical research protocol has been approved by the Medical Ethics Committee of the Second Affiliated Hospital of Army Medical University of the Chinese People's Liberation Army (Ethical review number: 2022-Research No. 019-01) and has passed the review of the Chinese Clinical Trial Registry (Registration number: ChiCTR2200063330). All participants provided written informed consent.

[0115] 2) Research subjects

[0116] Twenty adult patients with cholestatic liver disease who voluntarily participated in the research in the Second Affiliated Hospital of Army Medical University were used as the source of research subjects.

[0117] 3) Control and intervention measures

[0118] This study adopted a randomized controlled trial research method, and randomly divided patients with cholestatic liver disease who met the inclusion criteria into two groups. On the basis of oral treatment with the clinical basic drug ursodeoxycholic acid UDCA, the experimental group took a fixed dose of 1g of compound Lactobacillus acidophilus tablets every day before each meal, while the control group did not take it for a total of 14 days. Stool and serum samples were collected before and after medication. In order to minimize the risk of clinical trials, this trial did not use single-bacterial preparations of Lactobacillus acidophilus, but used compound Lactobacillus acidophilus tablets. Compound Lactobacillus acidophilus tablets are a commercially available conventional drug used in clinical practice. They are compound tablets composed of four bacterial powders, including Chinese strains of Lactobacillus acidophilus, Japanese strains of Lactobacillus acidophilus, faecal streptococci, and Bacillus subtilis.

[0119] 4) Evaluation indicators

[0120] 16S rRNA sequencing was performed on the fecal samples of the volunteers to analyze the changes in the composition and structure of the intestinal flora;

[0121] Liver function: detect the absolute changes in the serum ALT, AST, ALP, and GGT indicators of the participants;

[0122] Other information mainly includes: ① Basic information of the case: name, gender, age, height, weight, ethnicity, etc.; ② History of disease / surgery; ③ Eating habits, etc.

[0123] Assess safety: record the number of adverse reactions.

[0124] (2) Main methods

[0125] 1) Detection of peripheral blood liver function

[0126] The blood samples were sent to the laboratory department of the Second Affiliated Hospital of the Third Military Medical University (Xinqiao Hospital) for laboratory index testing.

[0127] 2) 16S rRNA sequencing and analysis

[0128] The detection method is the same as that in Example 2.

[0129] 3) Bile acid quantitative analysis

[0130] The detection method is the same as that in Example 3.

[0131] Experimental Results

[0132] Compared with the control group, AST, ALT, GGT and TBIL in patients with cholestatic liver disease treated with Lactobacillus acidophilus were significantly reduced (p<0.05); correlation analysis showed that the relative abundance of Lactobacillus was negatively correlated with serum ALT (R=-0.8571, P=0.0107), AST (R=-0.9762, P=0.0004), GGT (R=-0.6691, P=0.0696), and TBIL (R=-0.7619, P=0.0368) ( Figure 7 A-7E), suggesting that Lactobacillus acidophilus has the effect of improving cholestatic liver disease. Fecal 16S rRNA sequencing analysis showed that there was a significant difference in the diversity of intestinal flora after treatment with Lactobacillus acidophilus ( Figure 8 AD), indicating that the composition of the intestinal microbiota has changed. Further bile acid metabolism analysis showed that the serum total bile acid level of patients with cholestatic liver disease treated with Lactobacillus acidophilus decreased, fecal bile acid excretion increased (p<0.05), and more unconjugated bile acids (p<0.05) ( Fig. 9 AD).

[0133] Combined with the results of the above-mentioned experiments on the relationship between Lactobacillus acidophilus and intestinal FXR signaling, it can be seen that treating BDL mice with Lactobacillus acidophilus can alleviate the indicators and symptoms related to cholestatic liver injury, and Lactobacillus acidophilus plays a role in treating liver injury by enhancing the expression of ileal FXR downstream signaling genes in mice.

[0134] According to the literature (Wu Junfeng. Analysis of the efficacy of ursodeoxycholic acid combined with probiotics in the treatment of infant cholestatic liver disease [J]. Northern Pharmacy, 2021, 18 (10): 97-98.), UDCA and probiotics are used in combination to treat infant cholestatic liver disease. Compared with the single-drug group, the improvement of liver function indicators and serological indicators and the efficacy of the combined medication group are better. Unlike this study, the probiotics used in this study are Bacillus subtilis and live bacteria, and are used for infant patients. The cause of infantile cholestasis is generally different from that of adult cholestatic liver disease patients. Most infant cholestasis is caused by congenital or autoimmune causes, while the cause of adult patients is more complicated and the course of the disease is longer, mostly chronic intrahepatic cholestasis. This study shows that the combination of Lactobacillus acidophilus and UDCA is more effective than the clinical basic drug UDCA for intrahepatic cholestatic liver disease in adult patients.

[0135] Compared with the prior art, the present invention has the following beneficial effects:

[0136] (1) This study discovered and confirmed that Lactobacillus acidophilus improves cholestatic liver disease by activating intestinal FXR-FGF15 to inhibit liver cholesterol 7α-hydroxylase CYP7A1, providing a new intervention method for the prevention and / or treatment of clinical cholestatic liver disease patients;

[0137] (2) This study found and confirmed that Lactobacillus acidophilus can promote the excretion of unconjugated bile acids in mammals;

[0138] (3) This study confirmed through animal experiments that taking Lactobacillus acidophilus suspension can change the intestinal flora of adult mice, inhibit bile acid synthesis and promote excretion, and alleviate liver damage caused by cholestasis, indicating that active Lactobacillus acidophilus has the potential to be used as a drug for the treatment of intrahepatic cholestasis in mammals;

[0139] (4) This study confirmed through preliminary clinical trials that after taking a regular dose of a compound Lactobacillus acidophilus preparation for a period of time, the intestinal flora structure of patients with cholestatic liver disease changed and their liver function further improved, indicating that the compound Lactobacillus acidophilus tablets have the potential to be used as a clinical drug.

[0140] Finally, it should be noted that the above description is only a preferred embodiment of the present invention. Under the guidance of the present invention, ordinary technicians in this field can make various similar expressions without violating the purpose and claims of the present invention, and such changes all fall within the scope of protection of the present invention.

Claims

1. Use of Lactobacillus acidophilus in the preparation of a medicament for regulating the intestinal flora of humans or other mammals.

2. The use according to claim 1, characterized in that: Lactobacillus acidophilus is used as the only active bacteria in the medicament or together with active bacteria of other species.

3. Use of Lactobacillus acidophilus in the preparation of a medicament for treating intrahepatic cholestatic liver disease in humans or other mammals.

4. The use according to claim 3, characterized in that: The drug can regulate intestinal flora, reduce bile acid synthesis and promote bile acid excretion.

5. The use according to claim 3, characterized in that: The drug can increase the abundance of Lactobacillus acidophilus in the intestinal flora of humans or other mammals, and inhibit hepatic bile acid synthesis by activating small intestinal farnesoid X receptor signals.

6. The use according to claim 3, characterized in that: The drug increases the abundance of lactobacillus bacteria in the intestines of humans or other mammals and improves the ratio of unconjugated bile acid by enhancing the activity of bile salt hydrolase, thereby promoting fecal bile acid excretion.

7. The use according to any one of claims 3 to 6, characterized in that: The medicine contains Lactobacillus acidophilus and may or may not contain pharmaceutical auxiliary agents.

8. The use according to any one of claims 3 to 6, characterized in that: The medicine contains only one active bacterium, Lactobacillus acidophilus, or the medicine also contains active bacteria of other species.

9. Use of compound Lactobacillus acidophilus tablets in the preparation of a medicament for treating intrahepatic cholestatic liver disease in humans or other mammals, the compound Lactobacillus acidophilus tablets comprising four bacterial powders of Chinese strain Lactobacillus acidophilus, Japanese strain Lactobacillus acidophilus, Streptococcus faecalis and Bacillus subtilis.

10. Use of compound Lactobacillus acidophilus tablets in combination with ursodeoxycholic acid in the preparation of a medicament for treating intrahepatic cholestatic liver disease in humans or other mammals.